What's in Store for These 5 Biotech Stocks This Earnings Season?

Industry Overview - The fourth-quarter 2024 earnings season for the Medical sector is concluding, with major companies reporting results, primarily in pharma/biotech and medical devices [1] - As of February 19, 85.2% of companies in the Medical sector reported quarterly earnings, with 82.7% surpassing earnings estimates and 78.8% exceeding revenue expectations [2] - Year-over-year earnings increased by 14.2%, while revenues rose by 9.4%, with overall fourth-quarter earnings expected to increase by 13.8% and sales by 9.3% compared to the previous year [2] Company Summaries Viatris (VTRS) - Viatris has a mixed earnings surprise history, beating estimates in two of the last four quarters with an average surprise of 0.33% [4] - For the upcoming quarter, Viatris has an Earnings ESP of -3.51% and a Zacks Rank of 4, with a consensus estimate for earnings per share at 57 cents [6] - Sales growth is anticipated from emerging markets and business expansion in Greater China, alongside improved performance in the generics business due to new product launches [7] Perrigo (PRGO) - Perrigo also has a mixed earnings surprise history, beating estimates in three of the last four quarters with an average surprise of 8.41% [8] - The company has an Earnings ESP of -4.92% and a Zacks Rank of 4, with a consensus estimate for earnings per share at 92 cents [8] - Revenue declines are expected in its Consumer Self Care segments due to lower net product sales in the U.S. and unfavorable currency movements [9] Novavax (NVAX) - Novavax has struggled, missing earnings expectations in three of the last four quarters, with an average negative surprise of 56.95% [11] - The company has an Earnings ESP of -48.54% and a Zacks Rank of 3, with a consensus estimate for a loss per share at 75 cents [11] - Vaccine sales for Novavax are expected to be minimal during the quarter [12] Intellia Therapeutics (NTLA) - Intellia has a mixed earnings surprise history, beating estimates in three of the last four quarters with an average surprise of 4.02% [13] - The company has an Earnings ESP of +35.03% and a Zacks Rank of 2, indicating a good chance of an earnings beat, with a consensus estimate for a loss per share at $1.32 [14] - Revenue is likely to be driven by collaboration revenues, with updates on clinical-stage pipeline candidates expected during the conference call [15] Iovance Biotherapeutics (IOVA) - Iovance has a mixed earnings surprise history, beating estimates in three of the last four quarters with an average surprise of 5.55% [16] - The company has an Earnings ESP of +7.90% and a Zacks Rank of 4, with a consensus estimate for a loss per share at 27 cents [16] - Revenue growth is anticipated from sales of its marketed drugs, Proleukin and the recently-approved TIL therapy Amtagvi [17]